Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shanxi Univ. Cdc42 compound 6
- Development stage
- Unknown
- Lead developer
- Shanxi University
01
Overview
Shanxi Univ. Cdc42 compound 6: sourced facts only. name: "CETSA verification showed that compound 6 could enhance the thermal stability of Cdc42 (∆Tm >5 °C), suggesting Cdc42 as a potential antitumor target for this compound." [PMID:41061518]; target: "CETSA verification showed that compound 6 could enhance the thermal stability of Cdc42 (∆Tm >5 °C), suggesting Cdc42 as a potential antitumor target for this compound." [PMID:41061518]; developer: "Key Laboratory of Chemical Biology and Molecular Engineering of Education Ministry, Institute of Molecular Science, Shanxi University, Taiyuan 030006, PR China. Electronic address: [email protected]." [PMID:41061518]
02
Targets
CDC42 (Cell division control protein 42 homolog)
Beyond the preview
Go deeper on Shanxi Univ. Cdc42 compound 6.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shanxi Univ. Cdc42 compound 6.